» Articles » PMID: 24074565

Distinct Host Cell Fates for Human Malignant Melanoma Targeted by Oncolytic Rodent Parvoviruses

Overview
Journal Virology
Specialty Microbiology
Date 2013 Oct 1
PMID 24074565
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The rodent parvoviruses are known to be oncoselective, and lytically infect many transformed human cells. Because current therapeutic regimens for metastatic melanoma have low response rates and have little effect on improving survival, this disease is a prime candidate for novel approaches to therapy, including oncolytic parvoviruses. Screening of low-passage, patient-derived melanoma cell lines for multiplicity-dependent killing by a panel of five rodent parvoviruses identified LuIII as the most melanoma-lytic. This property was mapped to the LuIII capsid gene, and an efficiently melanoma tropic chimeric virus shown to undergo three types of interaction with primary human melanoma cells: (1) complete lysis of cultures infected at very low multiplicities; (2) acute killing resulting from viral protein synthesis and DNA replication, without concomitant expansion of the infection, due to failure to export progeny virions efficiently; or (3) complete resistance that operates at an intracellular step following virion uptake, but preceding viral transcription.

Citing Articles

H-1 Parvovirus as a Cancer-Killing Agent: Past, Present, and Future.

Bretscher C, Marchini A Viruses. 2019; 11(6).

PMID: 31216641 PMC: 6630270. DOI: 10.3390/v11060562.


Optimizing the Targeting of Mouse Parvovirus 1 to Murine Melanoma Selects for Recombinant Genomes and Novel Mutations in the Viral Capsid Gene.

Marr M, DAbramo A, Pittman N, Agbandje-Mckenna M, Cotmore S, Tattersall P Viruses. 2018; 10(2).

PMID: 29385689 PMC: 5850361. DOI: 10.3390/v10020054.


Atomic Resolution Structure of the Oncolytic Parvovirus LuIII by Electron Microscopy and 3D Image Reconstruction.

Pittman N, Misseldine A, Geilen L, Halder S, Smith J, Kurian J Viruses. 2017; 9(11).

PMID: 29084163 PMC: 5707528. DOI: 10.3390/v9110321.


Genome sequence of tumor virus x, a member of the genus protoparvovirus in the family parvoviridae.

Vollmers E, DAbramo Jr A, Cotmore S, Tattersall P Genome Announc. 2014; 2(4).

PMID: 25081268 PMC: 4118071. DOI: 10.1128/genomeA.00758-14.


Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer.

Angelova A, Grekova S, Heller A, Kuhlmann O, Soyka E, Giese T J Virol. 2014; 88(10):5263-76.

PMID: 24574398 PMC: 4019131. DOI: 10.1128/JVI.03688-13.

References
1.
Paradiso P . Infectious process of the parvovirus H-1: correlation of protein content, particle density, and viral infectivity. J Virol. 1981; 39(3):800-7. PMC: 171312. DOI: 10.1128/JVI.39.3.800-807.1981. View

2.
Tworkoski K, Singhal G, Szpakowski S, Zito C, Bacchiocchi A, Muthusamy V . Phosphoproteomic screen identifies potential therapeutic targets in melanoma. Mol Cancer Res. 2011; 9(6):801-12. PMC: 3117976. DOI: 10.1158/1541-7786.MCR-10-0512. View

3.
Prestwich R, Harrington K, Pandha H, Vile R, Melcher A, Errington F . Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Ther. 2008; 8(10):1581-8. PMC: 2729453. DOI: 10.1586/14737140.8.10.1581. View

4.
Cotmore S, Tattersall P . Genome packaging sense is controlled by the efficiency of the nick site in the right-end replication origin of parvoviruses minute virus of mice and LuIII. J Virol. 2005; 79(4):2287-300. PMC: 546602. DOI: 10.1128/JVI.79.4.2287-2300.2005. View

5.
Bloom M, Berry B, Wei W, Perryman S, Wolfinbarger J . Characterization of chimeric full-length molecular clones of Aleutian mink disease parvovirus (ADV): identification of a determinant governing replication of ADV in cell culture. J Virol. 1993; 67(10):5976-88. PMC: 238019. DOI: 10.1128/JVI.67.10.5976-5988.1993. View